Business
Positive results for Clarava from validation study
Positive results for Clarava from validation study.
About this update from Verici Dx Plc
[{"type":"text","content":"\n \n \n \n Verici Dx plc\n \n \n \n (\"Verici Dx\" or the \"Company\") \n \n \n \n \n \n \n \n \n Positive results for Clarava™ from blinded multi-centre clinical validation study\n \n \n \n \n \n \n \n \n \n Data validates Clarava's ability to identify patients likely to experience future kidney transplant rejection\n \n \n \n \n \n \n \n \n Verici Dx plc (AIM: VRCI), a developer of advanced clinical diagnostics for organ transplant,\n announces the successful outcomes from its blinded, international, multi-centre validation study for Clarava™, the Company's pre-transplant blood-basedprognostic test for the risk of early acute kidney transplant rejection.\n \n \n \n \n \n Utilising a diverse validation population from 14 international transplant sites, the initial results of the validation study amongst the US kidney transplant patients followed up to date show that the Clarava™ diagnostic, which uses next-generation RNA sequencing, is an effective tool to identify patients likely to experience a future transplant rejection event prior to their surgery.\n \n \n \n \n \n Clarava™ represents a novel pre-transplant approach to characterising a patient's immune-profile using their RNA signature. This is expected to have wide-ranging implications regarding treatment plans for each patient ahead of transplant, post-operatively and in terms of monitoring patient response. The Directors believe that the available data on Clarava™ positions it as a viable and compelling product for a broader patient population and commercialisation, as it has no directly competing products. These initial results from the Clarava™ validation study therefore mark a further, important step toward clinical acceptance and commercialisation of the test.\n \n \n \n \n \n To generate broad clinical acceptance within the diverse international transplant community, Verici Dx is extending enrolment in its ongoing clinical validation study for an additional six-month period, using its existing network of 14 international transplant centres across Europe as well as the US. The expansion of the Clarava™ validation cohort is designed to enrich the utility data for the assay and support a statistically robust and clinically meaningful case for its adoption in due course. \n \n \n \n \n \n \n \n Sara Barrington, CEO, ...